Crescent Biopharma files 424B3 prospectus; offering terms not specified in filing

Filed April 29, 2026 · ~1 min read

Key Changes

• high

  The 424B3 prospectus does not state the number of shares, price range, or use of proceeds for the offering.

  The Offering view on EDGAR →
• high

  The filing contains no company-specific risk factors, MD&A, or legal proceedings disclosures.

  Risk Factors verify on EDGAR →
• low

  Management states internal controls were effective as of March 31, 2026, with no changes during the quarter.

  Controls and Procedures verify on EDGAR →